Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma. (3rd May 2016)

• Record Type: Journal Article
• Authors: Crisafulli, Ernesto; Zanini, Andrea; Pisi, Giovanna; Pignatti, Patrizia; Poli, Gianluigi; Scuri, Mario; Chetta, Alfredo
• Is Part Of: Expert review of respiratory medicine. Volume 10:Number 5(2016)
• Page Start: 481
• Page End: 490
• Publication Date: 2016-05-03
• Subjects: Asthma -- small airways -- inflammation -- beclometasone dipropionate/formoterol fumarate -- extrafine -- fixed combination -- pMDI -- DPI; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1586/17476348.2016.1161508
• Languages: English
• ISSNs: 1747-6348

Abstract

ABSTRACT: Inhaled therapy is often considered the cornerstone of asthma management and international guidelines recommend combination therapy of inhaled corticosteroids (ICS) and long-acting-beta2-agonists (LABA) in a large proportion of asthmatic patients. The effectiveness of ICS/LABA is dependent on the correct choice of device and proper inhalation technique, this influences drug delivery and distribution along the bronchial tree, including the most peripheral airways. The fixed combination of beclometasone dipropionate/formoterol fumarate (BDP/FF) is the only extrafine formulation available in pressurized metered dose inhaler (pMDI) and in dry powder inhaler (DPI). Here, we focus on the recent significant advances regarding BDP/FF fixed combination for the treatment of asthma.